Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02809079

Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese Patients — MONICA  

Efficacy and Safety Clinical Trial

Official title:
Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese Patients

Clinical Trial Summary

Neuromyelitis optica (NMO) is an autoimmune inflammatory demyelinating disease of the central nervous system that leads to blindness and paralysis. Since disability accrues incrementally related to attacks, attack prevention with immunosuppressive therapy is the mainstay of preventing disability. However, there is no standard immunosuppressive treatment strategy for NMO relapse prevention. In a previous study, the investigators provided evidence supporting the use of azathioprine plus a low dose corticosteroid as an effective strategy which is associated with a reduction in the risk of relapse in Chinese patients with NMO, but azathioprine has bone marrow suppression and other side effects. Mycophenolate mofetil (MMF) is a new immunosuppressant with rapid onset, fewer side effects and other advantages. In recent years, MMF has been used in different immune-related neurological diseases; some literature shown the possible efficacy of MMF in NMO treatment.

In this research, a multi-center (Third Affiliated Hospital of Sun Yat-sen University, Zhongshan Ophthalmic Centre of Sun Yat-sen University, Nangfang Hospital of Southern Medical University) study will carry out to evaluate the efficacy and safety of mycophenolate mofetil therapy in NMO spectrum disorders.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02809079
Study type Interventional
Source Third Affiliated Hospital, Sun Yat-Sen University
Contact
Status Enrolling by invitation
Phase Phase 4
Start date January 2016
Completion date December 2017
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04759534 - Application of PCSK9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia Phase 3
Not yet recruiting NCT05532111 - Efficacy and Safety of the Treatment of Primary Membranous Nephropathy: A Randomized Clinical Trial N/A
Active, not recruiting NCT04284215 - Efficacy and Safety of Albumin Paclitaxel Combined With Cisplatin Chemoradiotherapy for Non-resectable Stage III NSCLC N/A
Completed NCT06202456 - A Phase IV Study of Huazhi Rougan Granule in the Treatment of Non-alcoholic Simple Fatty Liver Phase 4
Completed NCT04870606 - Proxalutamide (GT0918) Treatment for Outpatients With Mild or Moderate COVID-19 Illness Phase 3
Completed NCT03660761 - Apatinib in Recurrent or Refractory Intracranial Central Nervous System Malignant Tumors Phase 2
Active, not recruiting NCT03794778 - Evaluation of PLD Combined With Carboplatin Versus Paclitaxel Plus Carboplatin in the First-line Treatment of Epithelial Ovarian Cancer Phase 4
Recruiting NCT03255343 - Treatment of Non-responding to Conventional Therapy Inoperable Liver Cancers by in Situ Introduction of ImDendrim N/A
Recruiting NCT04197544 - Evaluation of the Implantation of the End-vascular Creation of the Arteriovenous Fistulas in Patients in the University Hospital of Araba. Pilot Study. N/A
Recruiting NCT04518501 - Fuzuloparib Arsenic Trioxide Platinum Resistance Relapsed Ovarian Cancer Phase 1/Phase 2
Completed NCT03779776 - The Efficacy and Safety of Early Vitamin AD Supplementation in Very Preterm Infants N/A
Not yet recruiting NCT06218004 - Envafolimab Combined With Chemotherapy in Neoadjuvant and Conversion Therapy for Head and Neck Squamous Cell Carcinoma Phase 2
Active, not recruiting NCT06194188 - A Phase 2 Clinical Study of CU-20401 Phase 2
Recruiting NCT03901235 - MSC Intratissular Injection in Crohn Disease Patients Phase 1/Phase 2
Completed NCT03826004 - Clemastine in Cardiovascular Surgery N/A
Active, not recruiting NCT03623776 - Neoadjuvant JS001, or JS001 in Combination With Pemetrexed and Carboplatin in Resectable NSCLC. Phase 2
Recruiting NCT04078399 - Efficacy and Safety of Azacitidine Combined With Interferon in the Treatment of Post-transplant Recurrence N/A
Not yet recruiting NCT06351735 - Efficacy and Safety of Deep Cervical Lymph Node-vein Bypass Surgery in ALS Amyotrophic Lateral Sclerosis
Not yet recruiting NCT06383078 - HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer Phase 2
Withdrawn NCT05481775 - Evaluating Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung Cancer Phase 2